Reduction in ambulatory visits for acute, uncomplicated bronchitis: an unintended but welcome result of the coronavirus disease 2019 (COVID-19) pandemic

Dilworth, Thomas J; Brummitt, Charles F

doi:10.1017/ice.2020.1233

Cited by 5 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, our findings reinforce previous studies of health care utilization 2 , 4 , 5 , influenza testing 3 , 8 , and non-COVID-19 viral symptoms 1 , 2 among pediatric patients in the United States, with additional findings that trends from late 2020 have generally continued through July 2021. Changes in the incidence of viral symptoms and positive tests may reflect changes in both disease incidence and care-seeking behavior.…”

Section: Discussionsupporting

confidence: 88%

“…Karen L. Margolis MD MPH 1 ; Stephen Waring DVM PhD 2 ; Julie Sonier MPA 3 ; Anupam B. Kharbanda MD MSc 4 ; Alanna M. Chamberlain PhD MPH 5 ; Lynn McFarling MD 6 ; Paul E. Drawz MD MHS MS 7 ; Karen Soderberg MPH 8 ; Vino S. Raj MD MBA 9 ; Ernest Krause BS 10…”

Section: Acknowledgementsmentioning

confidence: 99%

“…Studies from early interventions in the United States and abroad revealed spillover impacts of NPIs on reducing non-COVID-19 infectious disease incidence and related health care utilization among pediatric patients. [1][2][3][4][5][6][7][8][9] In the United States, the implementation and uptake of NPIs varied widely between states, age groups, and time periods, demonstrating a persistent need for locally targeted public health monitoring and policy response mechanisms. [10][11][12] Electronic health records (EHR) are a promising tool for public health surveillance, [13][14][15] but the vast majority of public health agencies in the United States are not readily able to access the breadth or depth of EHR data.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Trends in Pediatric Viral Symptoms, Influenza Testing, and SARS-CoV-2 Testing From a Statewide Electronic Health Record Consortium, January 2017 to July 2021

Khazanchi

Spaulding

Bodurtha

et al. 2021

Academic Pediatrics

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Acknowledgementsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Trends in Pediatric Viral Symptoms, Influenza Testing, and SARS-CoV-2 Testing From a Statewide Electronic Health Record Consortium, January 2017 to July 2021

Khazanchi

Spaulding

Bodurtha

et al. 2021

Academic Pediatrics

View full text Add to dashboard Cite

show abstract

“…Recent reports show that seasonal dynamics of common respiratory tract infections (RTIs) have almost vanished during the COVID-19 pandemic [16][17][18][19] . In England, overall fewer cases of common cold, flu, and bronchitis have been reported during the lockdown 20 .…”

Section: (Which Was Not Certified By Peer Review) Preprintmentioning

confidence: 99%

Viral kinetic modeling and clinical trial simulation predicts disruption of respiratory disease trials by non-pharmaceutical COVID-19 interventions

Arsène¹,

Couty²,

Faddeenkov³

et al. 2021

Preprint

View full text Add to dashboard Cite

Clinical research in infectious respiratory diseases has been profoundly affected by non-pharmaceutical interventions (NPIs) against COVID-19. On top of trial delays or even discontinuation which have been observed in all disease areas, NPIs altered transmission pattern of many seasonal respiratory viruses which followed regular patterns for decades before the pandemic. Clinical trial design based on pre-pandemic historical data therefore needs to be put in question. In this article, we show how knowledge-based mathematical modeling can be used to address this issue. We set up an epidemiological model of respiratory tract infection (RTI) sensitive to a time dependent between-host transmission rate and coupled this model to a mechanistic description of viral RTI episodes in an individual patient. By reducing the transmission rate when the lockdown was introduced in the United Kingdom in March 2020, we were able to reproduce the perturbed 2020 RTI disease burden data. Using this setup, we simulated several NPIs scenarios of various strength (none, mild, medium, strong) and conducted placebo-controlled in silico clinical trials in pediatric patients with recurrent RTIs (RRTI) quantifying annual RTI rate distributions. In interventional arms, virtual patients aged 1-5 years received the bacterial lysate OM-85 (approved in several countries for the prevention of pediatric RRTIs) through a pro-type I immunomodulation mechanism of action described by a physiologically based pharmacokinetics and pharmacodynamics approach (PBPK/PD). Our predictions showed that sample size estimates based on the ratio of RTI rates (or the post-hoc power of fixed sample size trials) are not majorly impacted under NPIs which are less severe (none, mild and medium NPIs) than a strict lockdown (strong NPI). However, NPIs show a stronger impact on metrics more relevant for assessing the clinical relevance of the effect such as absolute benefit. This dichotomy shows the risk that successful trials (even with their primary endpoints being met) still get challenged in risk benefit assessment during the review of market authorization. Furthermore, we found that a mild NPI scenario already affected the time to recruit significantly when sticking to eligibility criteria complying with historical data. In summary, our model predictions can help rationalize and forecast post-COVID-19 trial feasibility. They advocate for gauging absolute and relative benefit metrics as well as clinical relevance for assessing efficacy hypotheses in trial design and they question eligibility criteria misaligned with the actual disease burden.

show abstract

Innovations in Ambulatory Stewardship

Chang

Bao

Cowman

et al. 2022

Infection Prevention

View full text Add to dashboard Cite

Reduction in ambulatory visits for acute, uncomplicated bronchitis: an unintended but welcome result of the coronavirus disease 2019 (COVID-19) pandemic

Abstract: Financial support. No financial support was provided relevant to this article.

Cited by 5 publications

References 7 publications

Trends in Pediatric Viral Symptoms, Influenza Testing, and SARS-CoV-2 Testing From a Statewide Electronic Health Record Consortium, January 2017 to July 2021

Trends in Pediatric Viral Symptoms, Influenza Testing, and SARS-CoV-2 Testing From a Statewide Electronic Health Record Consortium, January 2017 to July 2021

Viral kinetic modeling and clinical trial simulation predicts disruption of respiratory disease trials by non-pharmaceutical COVID-19 interventions

Innovations in Ambulatory Stewardship

Contact Info

Product

Resources

About